{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T04:30:44Z","timestamp":1688445044716},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1177\/2168479013500967","type":"journal-article","created":{"date-parts":[[2013,8,22]],"date-time":"2013-08-22T04:16:09Z","timestamp":1377144969000},"page":"706-714","update-policy":"http:\/\/dx.doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Lipodystrophy Is Common Among Ethiopian Patients on Highly Active Antiretroviral Therapy but Is Not Associated With Quality of Life or Medication Adherence"],"prefix":"10.1007","volume":"47","author":[{"given":"Nasir Tajure","family":"Wabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nezif Hussien","family":"Dekama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Desta Hiko","family":"Gemeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,30]]},"reference":[{"key":"47060706_CR1","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s15010-002-3044-7","volume":"30","author":"HH Hirsch","year":"2002","unstructured":"Hirsch HH, Battegay M. Lipodystrophy syndrome by HAART in HIV-infected patients: manifestation, mechanisms and management. Infection. 2002;30:293\u2013298.","journal-title":"Infection"},{"issue":"5","key":"47060706_CR2","first-page":"7","volume":"44","author":"O Omolayo","year":"2008","unstructured":"Omolayo O, Sealy PL. HIV lipodystrophy syndrome. Hosp Physician. 2008;44(5):7\u201314.","journal-title":"Hosp Physician"},{"key":"47060706_CR3","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1097\/00002030-200110190-00003","volume":"15","author":"A Shevitz","year":"2001","unstructured":"Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update. AIDS. 2001;15:1917\u20131930.","journal-title":"AIDS"},{"issue":"suppl3","key":"47060706_CR4","first-page":"S197","volume":"14","author":"S Mauss","year":"2000","unstructured":"Mauss S. HIV-associated lipodystrophy syndrome. AIDS. 2000;14(suppl 3):S197\u2013S207.","journal-title":"AIDS"},{"key":"47060706_CR5","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","volume":"12","author":"A Carr","year":"1998","unstructured":"Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51\u2013F58.","journal-title":"AIDS"},{"issue":"suppl2","key":"47060706_CR6","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1086\/313854","volume":"30","author":"A Carr","year":"2000","unstructured":"Carr A. HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis. 2000;30(suppl 2):S135\u2013S142.","journal-title":"Clin Infect Dis"},{"key":"47060706_CR7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/00002030-200101260-00024","volume":"15","author":"C Goujard","year":"2001","unstructured":"Goujard C, Boufassa F, Deveaa C, et al. Incidence of clinical lipodystrophy in HIV-1 infected patients treated during primary infection. AIDS. 2001;15:282\u2013284.","journal-title":"AIDS"},{"key":"47060706_CR8","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/135965350400900317","volume":"9","author":"M Valk van der","year":"2004","unstructured":"van der Valk M, Casula M, Weverling GJ, et al. Prevalence of lipoatrophy and mitochondrial DNA content of blood and subcutaneous fat in HIV-1-infected patients randomly allocated to zidovudine- or stavudine-based therapy. Antivir Ther. 2004;9:385\u2013393.","journal-title":"Antivir Ther"},{"key":"47060706_CR9","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1086\/651117","volume":"50","author":"P Domingo","year":"2010","unstructured":"Domingo P, Cabeza MC, Pruvost A, et al. Relationship between HIV\/highly active antiretroviral therapy (HAART)\u2013associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin Infect Dis. 2010;50:1033\u20131040.","journal-title":"Clin Infect Dis"},{"key":"47060706_CR10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00002030-199903110-00004","volume":"13","author":"C Gervasoni","year":"1999","unstructured":"Gervasoni C, Ridolfo AL, Trifir\u00f2 G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465\u2013471.","journal-title":"AIDS"},{"key":"47060706_CR11","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(98)08468-2","volume":"353","author":"A Carr","year":"1999","unstructured":"Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093\u20132099.","journal-title":"Lancet"},{"issue":"10","key":"47060706_CR12","first-page":"443","volume":"5","author":"A Schwenk","year":"2000","unstructured":"Schwenk A, Breuer JP, Kremer G, et al. Risk factors for the HIV-associated lipodystrophy syndrome in a cross-sectional single-centre study. Eur J Med Res. 2000;5(10):443\u2013448.","journal-title":"Eur J Med Res"},{"issue":"6","key":"47060706_CR13","first-page":"605","volume":"87","author":"S Puttawong","year":"2004","unstructured":"Puttawong S, Prasithsirikul W, Vadcharavivad S. Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai. 2004;87(6):605\u2013611.","journal-title":"J Med Assoc Thai"},{"key":"47060706_CR14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1592\/phco.20.1.13.34667","volume":"20","author":"RB Qaqish","year":"2000","unstructured":"Qaqish RB, Fisher E, Rublein J, Wohl DA. HIV associated lipodystrophy syndrome. Pharmacotherapy. 2000;20:13\u201322.","journal-title":"Pharmacotherapy"},{"key":"47060706_CR15","first-page":"123","volume":"17","author":"S Reus","year":"2000","unstructured":"Reus S, Arroyo E, Boix V, Portilla J. Lipodystrophy and hyperglycemia produced by protease inhibitors. Ann Med Intern. 2000;17:123\u2013126.","journal-title":"Ann Med Intern"},{"key":"47060706_CR16","unstructured":"Behrens G, Schmidt RW. Lipodystrophy syndrome. Published 2011. http:\/\/hivbook.com\/2011\/10\/23\/lipodystrophy-syndrome\/."},{"issue":"8","key":"47060706_CR17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.trstmh.2007.02.020","volume":"101","author":"J Griensven Van","year":"2007","unstructured":"VanGriensven J, De Naeyer L, Mushi T, et al. High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda. Trans R Soc Trop Med Hygiene. 2007;101(8):793\u2013798.","journal-title":"Trans R Soc Trop Med Hygiene"},{"key":"47060706_CR18","first-page":"131","volume":"19","author":"J Womack","year":"2009","unstructured":"Womack J. HIV-related lipodystrophy in Africa and Asia. AIDS Reader. 2009;19:131\u2013139, 148\u2013152.","journal-title":"AIDS Reader"},{"key":"47060706_CR19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1097\/00002030-200105040-00005","volume":"15","author":"M Valk van der","year":"2001","unstructured":"van der Valk M, Gisolf EH, Reiss P, et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS. 2001;15:847\u2013855.","journal-title":"AIDS"},{"issue":"2","key":"47060706_CR20","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1161\/CIRCULATIONAHA.107.189623","volume":"118","author":"C Grunfeld","year":"2008","unstructured":"Grunfeld C, Kotler DP, Arnett DK, et al. Contribution of metabolic and anthropometric abnormalities to cardiovascular disease risk factors. Circulation. 2008;118(2):e20\u2013e28.","journal-title":"Circulation"},{"key":"47060706_CR21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1742-6405-4-19","volume":"4","author":"E Mutimura","year":"2007","unstructured":"Mutimura E, Stewart A, Crowther NJ. Assessment of quality of life in HAART-treated HIV-positive subjects with body fat redistribution in Rwanda. AIDS Res Ther. 2007;4:19.","journal-title":"AIDS Res Ther"},{"key":"47060706_CR22","first-page":"546","volume":"10","author":"E Collins","year":"2000","unstructured":"Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader. 2000;10:546\u2013550.","journal-title":"AIDS Reader"},{"key":"47060706_CR23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"The EuroQol Group.","year":"1990","unstructured":"The EuroQol Group. EuroQola new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"issue":"11","key":"47060706_CR24","first-page":"529","volume":"3","author":"CG Silva","year":"2011","unstructured":"Silva CG, Alchieri JC. Esthetic self-perception of HIV\/AIDS patients under antiretroviral therapy suffering from lipodystrophic syndrome and its influence on the quality of life in a city of the Brazilian northeast. J Public Health Epidemiol. 2011;3(11):529\u2013535.","journal-title":"J Public Health Epidemiol"},{"key":"47060706_CR25","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1023\/B:QURE.0000018485.05372.d6","volume":"13","author":"V Noerholm","year":"2004","unstructured":"Noerholm V, Groenvold M, Watt T, Bjorner JB, Rasmussen NA, Bech P. Quality of life in the Danish general population\u2014normative data and validity of WHOQOLBREF using Rasch and item response theory models. Qual Life Res. 2004;13:531\u2013540.","journal-title":"Qual Life Res"},{"key":"47060706_CR26","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/00126334-200212010-00006","volume":"31","author":"J Blanch","year":"2002","unstructured":"Blanch J, Rousaud A, Mart\u00fdnez E, et al. Impact of lipodystrophy on the quality of life of HIV-1\u2013infected patients. J Acquir Immune Defic Syndr. 2002;31:404\u2013407.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"47060706_CR27","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s11136-004-2580-2","volume":"14","author":"R Burgoyne","year":"2005","unstructured":"Burgoyne R, Collins E, Wagner C, et al. The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. Qual Life Res. 2005;14:981\u2013990.","journal-title":"Qual Life Res"},{"issue":"7","key":"47060706_CR28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/apc.2007.0173","volume":"22","author":"G Guaraldi","year":"2008","unstructured":"Guaraldi G, Murri R, Orlando G, et al. Severity of lipodystrophy is associated with decreased health-related quality of life. AIDS Patient Care STDS. 2008;22(7):577\u2013585.","journal-title":"AIDS Patient Care STDS"},{"key":"47060706_CR29","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","volume":"15","author":"SA Duran","year":"2001","unstructured":"Duran SA, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441\u20132444.","journal-title":"AIDS"},{"key":"47060706_CR30","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.1097\/00126334-200212153-00011","volume":"31","author":"A Ammassari","year":"2002","unstructured":"Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr. 2002;31:S140\u2013S144.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"47060706_CR31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1089\/apc.2006.128","volume":"21","author":"PC Tien","year":"2007","unstructured":"Tien PC, Barron Y, Justman JE, et al. Antiretroviral therapies associated with lipoatrophy in HIV-infected women. AIDS Patient Care STDS. 2007;21:297\u2013305.","journal-title":"AIDS Patient Care STDS"},{"issue":"9","key":"47060706_CR32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/apc.2005.19.577","volume":"19","author":"IB Corless","year":"2005","unstructured":"Corless IB, Kirksey KM, Kemppainen J, et al. Lipodystrophy-associated symptoms and medication adherence in HIV\/AIDS. AIDS Patient Care STDS. 2005;19(9):577\u2013586.","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"47060706_CR33","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/09540120412331305098","volume":"17","author":"SB Mannheimer","year":"2005","unstructured":"Mannheimer SB, Matts J, Telzak E, et al. Quality of life in HIV-infected individuals receiving antiretroviral therapy is related to adherence. AIDS Care. 2005;17(1):10\u201322.","journal-title":"AIDS Care"},{"key":"47060706_CR34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/108729102760330254","volume":"16","author":"M Oette","year":"2002","unstructured":"Oette M, Juretzko P, Kroidl A, et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care STDS. 2002;16:413\u2013417.","journal-title":"AIDS Patient Care STDS"},{"key":"47060706_CR35","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/09540120500287051","volume":"18","author":"NR Reynolds","year":"2006","unstructured":"Reynolds NR, Neidig JL, Wu AW, et al. Balancing disfigurement and fear of disease progression: patient perceptions of HIV body fat redistribution. AIDS Care. 2006;18:663\u2013673.","journal-title":"AIDS Care"},{"key":"47060706_CR36","volume-title":"WHOQOL-BREF: Introduction, Administration, Scoring and Generic Version of the Assessment","author":"World Health Organization Programme on Mental Health.","year":"1996","unstructured":"World Health Organization Programme on Mental Health. WHOQOL-BREF: Introduction, Administration, Scoring and Generic Version of the Assessment. Geneva, Switzerland: World Health Organization; 1996."},{"issue":"9256","key":"47060706_CR37","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","volume":"357","author":"E Martinez","year":"2001","unstructured":"Martinez E, Mocroft A, Garc\u00eda-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357(9256):592\u2013598.","journal-title":"Lancet"},{"key":"47060706_CR38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1468-1293.2001.00073.x","volume":"2","author":"VM Carter","year":"2001","unstructured":"Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med. 2001;2:174\u2013180.","journal-title":"HIV Med"},{"key":"47060706_CR39","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1097\/00002030-200007070-00002","volume":"14","author":"S Mallal","year":"2000","unstructured":"Mallal S, John M, Moore C, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in HIV infection. AIDS. 2000;14:1309\u20131316.","journal-title":"AIDS"},{"key":"47060706_CR40","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1086\/651117","volume":"50","author":"P Domingo","year":"2010","unstructured":"Domingo P, Cabeza MC, Pruvost A, et al. Relationship between HIV\/highly active antiretroviral therapy (HAART)\u2013associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin Infect Dis. 2010;50:1033\u20131040.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"47060706_CR41","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1086\/338811","volume":"34","author":"G Ch\u00eane","year":"2002","unstructured":"Ch\u00eane G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis. 2002;34(5):649\u2013657.","journal-title":"Clin Infect Dis"},{"key":"47060706_CR42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1023\/B:QURE.0000018485.05372.d6","volume":"13","author":"V Noerholm","year":"2004","unstructured":"Noerholm V, Groenvold M, Watt T, Bjorner JB, Rasmussen NA, Bech P. Quality of life in the Danish general population\u2014normative data and validity of WHOQOLBREF using Rasch and item response theory models. Qual Life Res. 2004;13:531\u2013540.","journal-title":"Qual Life Res"},{"key":"47060706_CR43","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/00126334-200212010-00006","volume":"31","author":"J Blanch","year":"2002","unstructured":"Blanch J, Rousaud A, Mart\u00fdnez E, et al. Impact of lipodystrophy on the quality of life of HIV-1\u2013infected patients. J Acquir Immune Defic Syndr. 2002;31:404\u2013407.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"47060706_CR44","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/00002030-200105250-00010","volume":"15","author":"W Schrooten","year":"2001","unstructured":"Schrooten W, Colebunders R, Youle M, et al. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS. 2001;15:1019\u20131023.","journal-title":"AIDS"},{"key":"47060706_CR45","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1097\/00002030-200104130-00025","volume":"15","author":"N Dukers","year":"2001","unstructured":"Dukers N, Stolte IG, Albrecht N, et al. The impact of experiencing lipodystrophy on the sexual behavior and well-being among HIV infected homosexual men. AIDS. 2001;15:812\u2013813.","journal-title":"AIDS"},{"key":"47060706_CR46","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1177\/135965350701200713","volume":"12","author":"G Guaraldi","year":"2007","unstructured":"Guaraldi G, Luzi K, Murri R, et al. Sexual dysfunction in HIV-infected men: role of antiretroviral therapy, hypogonadism and lipodystrophy. Antiviral Ther. 2007;12:1059\u20131065.","journal-title":"Antiviral Ther"},{"key":"47060706_CR47","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1097\/00002030-200112070-00012","volume":"15","author":"SA Duran","year":"2001","unstructured":"Duran SA, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 2001;15:2441\u20132444.","journal-title":"AIDS"}],"container-title":["Therapeutic Innovation & Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479013500967.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2168479013500967","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1177\/2168479013500967\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2168479013500967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1177\/2168479013500967.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:37:40Z","timestamp":1688431060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1177\/2168479013500967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["47060706"],"URL":"https:\/\/doi.org\/10.1177\/2168479013500967","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}